AZZ Inc. provides hot-dip galvanizing and coil coating solutions in North America. It offers metal finishing solutions for corrosion protection, including hot-dip galvanizing, spin galvanizing, powder coating, anodizing, and plating to steel fabrication and other industries, as well as to fabricators or manufacturers that provide services to the transmission and distribution, bridge and highway, petrochemical, and general industrial markets; and original equipment manufacturers. It also provides aesthetic and corrosion protective coatings and related value-added services for steel and aluminum coil primarily serving the construction; appliance; heating, ventilation, and air conditioning; container; transportation; and other end markets. The company was incorporated in 1956 and is headquartered in Fort Worth, Texas.

AZZ Inc.

In a report released today, Gerry Sweeney from Roth MKM maintained a Buy rating on AZZ, with a price target of $120.00. Sweeney covers the Industri...

Roth MKM Remains a Buy on AZZ (AZZ)

Aztec Minerals ( ($TSE:AZT) ) has issued an announcement. Aztec Minerals has announced an expansion of its drilling program at the Tombstone Projec...

Aztec Minerals Expands Tombstone Project Drilling Program

In a report released on November 28, from Goldman Sachs initiated coverage with a Buy rating on Addtech AB Class B and a price target of SEK370.00....

Addtech AB Class B (AZZ2) Has a New Rating from Goldman Sachs

Analysts are intrested in these 5 stocks: ( ($EXAS) ), ( ($REGN) ), ( ($MRVL) ), ( ($FROG) ) and ( ($JAZZ) ). Here is a breakdown of their recent


Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts

Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results for its gast...

Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets

In a report released today, from Jefferies maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $225.00. In addition to Jefferie...

Jefferies Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

All of the top stock market stories are ready to go in the TipRanks daily wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Jazz Pharmaceuticals stock gained on Monday after the company posted positive clinical trial data.


Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results

Jazz Pharmaceuticals ( ($JAZZ) ) has issued an announcement. On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3...

Current Quarter	$1.47	Next Quarter	$1.24
Current Year	$6.05	Next Year	$6.8
QoQ Growth	-15.6%	YoY Growth	+12.4%
3Y EPS CAGR	-18.9%	Target Price	$122.33
Consensus	Buy	Upside	+14.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AZZ	$107.17	-2.35%	206.26K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AZZ	$107.17	-2.4%	206.26K
3
4
5
6

AZZ

AZZ

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get AZZ Inc. Data in Excel

Get AZZ Inc. Data in Excel